REVUFORJ®

Hold Company

SYNDAX

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 25MG BASE; EQ 110MG BASE; EQ 160MG BASE

Indication

Revuforj® is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

Use

Instructions for Use

API

REVUMENIB CITRATE

API Structure

We Supply

REVUMENIB

Drug Patent

Patent No	Expiration Date
10683302	2037/6/8
11479557	2037/6/8

API Patent

Patent No	Expiration Date
10683302	2037/6/8
11479557	2037/6/8

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.